Document 0936
 DOCN  M9650936
 TI    [Gene therapy for AIDS: current trends]
 DT    9505
 AU    Takatsuki K; Obaru K; Yoshimura K; Matsushita S; Second Department of
       Internal Medicine, Kumamoto University; School of Medicine.
 SO    Nippon Rinsho. 1996 Jan;54(1):233-41. Unique Identifier : AIDSLINE
       MED/96155336
 AB    Genetic manipulation of somatic cells may be of therapeutic value in a
       variety of infectious diseases, particularly in human immunodeficiency
       virus (HIV) infection. Stable insertion of resistance genes into cells,
       susceptible to HIV, could reduce the viral burden in infected
       individuals and potentially retard the characteristic progressive immune
       dysfunction. Alternatively, ectopic expression of genes that encode
       viral antigens, might induce potent antiviral immune responses and form
       the basis for novel prophylactic and therapeutic vaccines. While
       laboratory studies have proved that the approach works in principle,
       preclinical and clinical studies will be necessary to evaluate the
       therapeutic benefits of such gene-based therapies. Currently, more than
       400 patients have already been treated by this innovative therapeutic
       strategy in the US. In Japan, the Expert Committee on Gene therapy was
       set up in the council on Science and the Public Health and Welfare in
       1991. Recently, gene therapy for ADA has been approved. It is thought
       that the first gene therapy against HIV infection in Japan is not far
       away.
 DE    Acquired Immunodeficiency Syndrome/*THERAPY  Animal  English Abstract
       Gene Therapy/*TRENDS  Gene Transfer  Genetic Vectors  Human
       HIV-1/*GENETICS/IMMUNOLOGY  Mutation  RNA, Catalytic  RNA, Viral
       JOURNAL ARTICLE  REVIEW  REVIEW, TUTORIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).